Islet transplantation is a potential cellular treatment of Type 1 diabetes. Reducing hypoxia-induced islet cell loss would significantly improve the efficiency of this procedure. In our lab, we have developed an oxygen-generating biomaterial, termed OxySite, as a means to support the cellular grafts. Incorporation of this material into a macro-scale transplantation device has shown the potential to eliminate hypoxia-induced cell dysfunction and death for both cell lines and primary pancreatic islets. As the next step towards clinical translation, we are currently investigating this material in vivo, and my goal is to characterize the properties of this material to optimize the design of the transplantation device.